Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Factors That Influence Compliance With Disease-Modifying Therapy in Multiple Sclerosis

This study has been completed.
Information provided by:
University of Texas Southwestern Medical Center Identifier:
First received: September 15, 2005
Last updated: January 23, 2007
Last verified: April 2005
The purpose of this study is to evaluate the coorelation between patient factors, health care provider factors, drug factors and compliance in patients with relapsing forms of multiple sclerosis (RMS) treated with Disease Modifying Agents (DMA). We hypothesize that a number of factors influence compliance with DMA's.

Condition Intervention
Multiple Sclerosis
Behavioral: Factors that influence compliance

Study Type: Observational
Study Design: Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Cross-Sectional
Time Perspective: Retrospective
Official Title: Factors That Influence Compliance With Disease-Modifying Therapy in Multiple Sclerosis

Resource links provided by NLM:

Further study details as provided by University of Texas Southwestern Medical Center:

Estimated Enrollment: 1040
Study Start Date: April 2004
Estimated Study Completion Date: September 2005
  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of relapsing form of multiple sclerosis
  • Age 18 or older
  • Therapy with disease modifying agent (Glatiramer acetate, Interferon Beta-1b, ot Interferon Beta 1a (IM or SC) for at least 6 months
  • Access to the internet to complete the study survey

Exclusion Criteria:

  • Diagnosis of progressive forms of multiple sclerosis
  • Therapy on DMA for less than 6 months
  • Inability to complete the survey
  • Participation in other investigational studies within the last 6 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00223457

United States, Texas
UT Southwestern Medical Center
Dallas, Texas, United States, 75390
Sponsors and Collaborators
University of Texas Southwestern Medical Center
Principal Investigator: Elliot M Frohman, MD, PhD University of Texas, Southwestern Medical Center at Dallas
Principal Investigator: Katherine D Treadaway, LCSW UT Southwestern Medical Center
  More Information

Publications: Identifier: NCT00223457     History of Changes
Other Study ID Numbers: MS DMA Compliance
Study First Received: September 15, 2005
Last Updated: January 23, 2007

Keywords provided by University of Texas Southwestern Medical Center:
multiple sclerosis
disease modifying therapy
quality of life

Additional relevant MeSH terms:
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases processed this record on May 23, 2017